Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: An update for recent advances in therapeutics

Journal of Oncology Pharmacy Practice

Volumn 22, Issue 3, 2016, Pages 461-476

  Chung, Clement ^a  

^a Lyndon B Johnson General Hospital   (United States)

Author keywords

acquired resistance; Epidermal growth factor receptor tyrosine kinase inhibitor; exon 19 deletion; exon 21 L858R gene substitution; novel; therapy

Indexed keywords

AFATINIB; ERLOTINIB; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ACNE; ADENOCARCINOMA; ARTHRALGIA; ASIAN; BACKACHE; CANCER CHEMOTHERAPY; CAUCASIAN; CONJUNCTIVITIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; ETHNICITY; EXON; EYE DISEASE; FEVER; GENE; GENE DELETION; GENE MUTATION; GENETIC SCREENING; HISTOLOGY; HUMAN; KERATOCONJUNCTIVITIS; LUNG ADENOCARCINOMA; LUNG CANCER; MUSCULOSKELETAL PAIN; NON SMALL CELL LUNG CANCER; PARONYCHIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; REVIEW; SIGNAL TRANSDUCTION; WEAKNESS; XERODERMA; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); GENETICS; LUNG TUMOR; MUTATION; PROCEDURES;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84964241130     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155215577810     Document Type: Review

References (83)

1. National Cancer Institute. SEER (Surveillance, Epidemiology and End Results) Statistics, http://seer.cancer.gov (accessed 11 August 2014).
2. Cancer staging handbook. 7th ed. AJCC cancer staging manual. Springer. 2009.
3. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 2003; 95: 1453-1461.
4. Albain KS, Crowley JJ, Turrisi AT 3rd, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 2002; 20: 3454-3460.
5. Socinski MA, Evans T, Gettinger S, et al. Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143: e341S-68S.
6. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non small-cell lung cancer. N Eng J Med 2002; 346: 92-98.
7. Cohen S,. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem 1962; 237: 1555-1562.
8. Bogdan S, Klämbt C,. Epidermal growth factor receptor signaling. Curr Biol 2001; 11: R292-R295.
9. Bazley LA, Gullick WJ,. The epidermal growth factor receptor family. Endocr Relat Cancer 2005; 12: S17-S27.
10. Ciardello F, Tortora G,. EGFR antagonists in cancer treatment. N Eng J Med 2008; 358: 1160-1174.
11. Fujino S, Enokibori T, Tezuka N, et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer 1996; 32A: 2070-2074.
12. Mendelsohn J, Baselga J,. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006; 33: 369-385.
13. Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 169-181.
14. Wells A,. EGFR receptor. Int J Biochem Cell Biol 1999; 31: 637-643.
15. Ciardiello F, Tortora G,. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7: 2958-2970.
16. Mitsudomi T, Yatabe Y,. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007; 98: 1817-1824.
17. Sequist LV, Bell DW, Lynch TJ, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007; 25: 587-595.
18. Riely GJ, Pao W, Li AR, et al. Clinical course of patients with nonsmall cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006; 12: 839-844.
19. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104: 20932-20937.
20. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-1043.
21. Kosaka T, Yamaki E, Mogi A, et al. Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol 2011; 2011: 165214-165214.
22. Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005; 65: 1642-1646.
23. Soung YH, Lee JW, Kim SY, et al. Somatic mutations of the ERBB4 kinase domain in human cancers. Int J Cancer 2006; 118: 1426-1429.
24. Naoki K, Chen TH, Richards WG, et al. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 2002; 62: 7001-7003.
25. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554-554.
26. Zhang Z, Lee JC, Lin L, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012; 44: 852-860.
27. NCCN Practice guidelines in Oncology. Version 4. 2014. Fort Washington, PA. The National Comprehensive Cancer Network, http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf (accessed 1 Sept 2014).
28. Miller VA, Johnson DH, Krug LM, et al. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. J Clin Oncol 2003; 21: 2094-2100.
29. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. (The IDEAL 1 Trial) [Corrected]. J Clin Oncol 2003; 21: 2237-2246.
30. Sequist LV, Yang JC-H, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung carcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327-3334.
31. Lee SM, Khan I, Upadhyay S, et al. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2012; 13: 1161-1170.
32. Crino L, Cappuzzo F, Zatloukal P, et al. Gefitinib versus vinorelbine in chemotherapy-naïve elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 2008; 26: 4253-4260.
33. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-2158.
34. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537.
35. Yang JC-H, Shih J-Y, Su W-C, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012; 13: 539-548.
36. Wu Y-L, Zhou C, Hu C-P, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised Phase III trial. Lancet Oncol 2014; 15: 213-222.
37. Clinicaltrials.gov. LUX-Lung 7: a Phase IIb trial of afatinib(BIBW2992) versus gefitinib for the treatment of 1st line EGFR mutation positive adenocarcinoma of the lung, http://clinicaltrials.gov/show/NCT01466660. (accessed 15 Feb 2015).
38. Clinicaltrials.gov. LUX-Lung 8: a Phase III trial of afatinib (BIBW 2992) versus erlotinib for the treatment of squamous cell lung cancer after at least one prior platinum based chemotherapy, http://clinicaltrials.gov/show/NCT01523587 (accessed 15 Feb 2015).
39. Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a Phase 2b/3 randomised trial. Lancet Oncol 2012; 13: 528-538.
40. Katakami N, Atagi S, Goto K, et al. LUX-lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 2013; 31: 3335-3341.
41. Schuler M, Yang C-H J, Park K, et al. Continuation of afatinib beyond progression: results of a randomized, open-label, Phase III trial of afatinib plus paclitaxel versus investigator's choice chemotherapy in patients with metastatic non-small-cell lung cancer (NSCLC) progressed on erlotinib/gefitinib and afatinib: LUX-Lung 5. In: Abstract #8019 presented at 2014 American Society of Clinical Oncology, 50th annual meeting, 30 May-3 June 2014, Chicago, IL, USA.
42. Spigel DR, Edelman MJ, O'Byrne K, et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: results from the pivotal phase III randomized, multicenter, placebo-controlled METlung (OAM4971g) global trial. In: ASCO annual meeting; Chicago, IL 2014. Abstract 8000.
43. Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 2014; 15: 1236-1244.
44. Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 9: 1046-1061.
45. Rosell R, Molina MA, Costa C, et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 2011; 17: 1160-1168.
46. Gazdar AF,. Activating and resistance mutations of EGFR in non-small cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009; 28: S24-S31.
47. Su KY, Chen HY, Lim KC, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small cell lung cancer. J Clin Oncol 2012; 30: 433-440.
48. Shepherd F, Tsao MS,. Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. J Clin Oncol 2006; 24: 1219-1220.
49. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non small-cell lung cancer. N Eng J Med 2005; 353: 123-132.
50. Leighl NB, Rekhtman N, Biermann WA, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline. J Clin Oncol 2014; 32: 3673-3679.
51. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): a mutlicentre, open-label, randomized phase 3 trial. Lancet Oncol 2011; 12: 735-742.
52. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004; 22: 777-784.
53. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004; 22: 785-794.
54. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 5892-5899.
55. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25: 1545-1552.
56. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11: 521-529.
57. Lee JS, Ignacio J, Yu C, et al. FAST-ACT: a phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26: 8031-8031.
58. Weickhardt A, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 2012; 7: 1807-1814.
59. Chaft JE, Oxnard GR, Sima CS, et al. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011; 17: 6298-6303.
60. Mitudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol 2010; 11: 121-128.
61. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Eng J Med 2010; 362: 2380-2388.
62. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, open-label, randomized, phase 3 study. Lancet Oncol 2011; 12: 735-742.
63. Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012; 343: 342-350.
64. Segaert S, Van Cutsem E,. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425-1433.
65. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J Clin Oncol 2004; 22: 3238-3247.
66. Jost M, Karl C, Rodeck U,. The EGF receptor-an essential regulator of multiple epidermal functions. Eur J Dermatol 2000; 10: 505-510.
67. de Noronha e Menezes NM, Lima R, et al. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients. Eur J Dematol 2009; 19: 248-251.
68. Li T, Kung HJ, Mack PC, et al. Genotyping and genomic profiling of non-small-cell lung cancer: implication for current and future therapies. J Clin Oncol 2013; 31: 1039-1049.
69. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Eng J Med 2005; 353: 123-132.
70. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 9496: 1527-1537.
71. Janjigian YY, Azzoli CG, Krug LM, et al. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin Cancer Res 2011; 17: 2521-2527.
72. Janjigian YY, Groen HJ, Horn L, et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol 2011; 29: Abstract 7525-Abstract 7525.
73. Mok TSK, Wu Y, Nakagawa K, et al. Gefitinib/chemotherapy vs chemotherapy in epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) after progression on first-line gefitinib: the Phase III Randomised IMPRESS Study. Ann Oncol 2014; 25: Abstract LBA2-PR-Abstract LBA2-PR.
74. Park K, Ahn M-J, Yu C-J, et al. ASPIRATION: first-line erlotinib (E) until and beyond RECIST progression (PD) in Asian patients (pts) with EGFR mutation-positive (mut+) NSCLC. Ann Oncol 2014; 25: iv426-iv427.
75. Sequist LV, Soria JC, Gadgeel SM, et al. First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M. J Clin Oncol 2013; 31: abstract #2524. Presented at 2013 American Society of Clinical Oncology, 49th Annual Meeting, 31 May-4 June 2013, Chicago, IL, USA.
76. Clinicaltrials.gov. Study to evaluate safety, pharmacokinetics, and efficacy of rociletinib (CO-1686) in previously treated mutant epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) patients, https://clinicaltrials.gov/ct2/show/NCT01526928 (accessed 18 Feb 2015).
77. Ranson M, Pao W, Kim DW, et al. AZD9291: an irreversible, potent and selective tyrosine kinase inhibitor (TKI) of activating (EGFR+) and resistance (T790M) mutations in advanced NSCLC. The AURA study. J Thorac Oncol 2013; 11-034. suppl; abstr P1.11.
78. Janne PA, Ramalingam SS, Yang JCH, et al. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC). In: Program and abstracts of the American Society of Clinical Oncology annual meeting; May 30-June 3, 2014; Chicago, Illinois. Abstract # 8009.
79. Pardoll DM,. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264.
80. Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465.
81. Azuma K, Ota K, Kawahara A, et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected non small-cell lung cancer. Ann Oncol 2014; 25: 1935-1940.
82. Bryant A, Cerfolio RJ,. Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. Chest 2007; 132: 185-192.
83. Goss GD, Felip E, Cobo M, et al. A randomized, open-label, phase III trial of afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: LUX-Lung 8 (LL8). Abstract #1222O Presented at the European Society for Medical Oncology (ESMO) 2014 Congress, Madrid, Spain, 26-30 September 2014.